STATKING Clinical Services Reaches 25 Year Milestone

Cincinnati, OH – November 18, 2014 – STATKING Clinical Services (SCS), a privately-owned, Cincinnati-based Contract Research Organization (CRO), has observed its 25th anniversary of service to the pharmaceutical and medical device industries. Since opening its doors in 1989, the CRO has provided services on over 300 clinical studies. STATKING has progressed from a biostatistics consulting company to a full service CRO providing a complete solution for the management of clinical trials. STATKING has been a key partner to its Client companies in multiple regulatory product approvals in multiple therapeutic areas. STATKING has provided valued, strategic input to over 100 companies in STATKING's niche market of emerging pharmaceutical and medical device companies. "Our progress as a CRO is truly a testament to the hard work of many dedicated employees over the past 25 years." commented Dennis W. King, Founder, President and CEO of STATKING Clinical Services, "We are proud of the dedication, honesty and integrity that our people and our management have shown in the operation of this company." Rod Lashley, Executive Vice President and Co-owner of STATKING,added "It is truly rewarding to know that we have helped so many companies obtain regulatory approval for their products. We look forward to continuing to be a valued partner for our clients."

About STATKING Clinical Services

STATKING Clinical Services provides clinical trial services (clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, contract laboratory services, safety reporting, and project management) for clinical trials for the regulatory approval of novel drug and medical device products. The company is headquartered in Fairfield, OH. The company has provided support on 12 NDAs, 13 PMAs and multiple NADAs over the past 25 years of service to the pharmaceutical, medical device and animal health industries. For more information, visit www.statkingclinical.com.

Contact
STATKING Clinical Services
Rod Lashley, Executive Vice President 513-858-2989 x303
[email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.